Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live03-09

Cynata Therapeutics' (ASX:CYP) acute graft-versus-host disease (aGvHD) drug candidate, CYP-001's potential has been reinforced by Mesoblast's (ASX:MSB) fiscal first half results, said Euroz Hartleys in a Monday note.

Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric (aGvHD), generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.

CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.

The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.

Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618617137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 14:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618617137","market":"fut","top_or_hot":-1,"title":"Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a>' (ASX:CYP) acute graft-versus-host disease (aGvHD) drug candidate, CYP-001's potential has been reinforced by Mesoblast's (ASX:MSB) fiscal first half results, said <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys in a Monday note.</p><p>Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric (aGvHD), generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.</p><p>CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.</p><p>The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.</p><p>Euroz Hartleys has maintained a speculative buy rating on Cynata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> with a price target of AU$0.90.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-09 14:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a>' (ASX:CYP) acute graft-versus-host disease (aGvHD) drug candidate, CYP-001's potential has been reinforced by Mesoblast's (ASX:MSB) fiscal first half results, said <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys in a Monday note.</p><p>Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric (aGvHD), generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.</p><p>CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.</p><p>The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.</p><p>Euroz Hartleys has maintained a speculative buy rating on Cynata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> with a price target of AU$0.90.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618617137","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618617137","pubTimestamp":1773038279,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cynata Therapeutics'  acute graft-versus-host disease  drug candidate, CYP-001's potential has been reinforced by Mesoblast's  fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric , generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MESO":"Mesoblast Limited","BK4539":"次新股","LENZ":"Therapeutics","CYP.AU":"CYNATA THERAPEUTICS LTD","BK4139":"生物科技","BK7067":"生物科技","MSB.AU":"MESOBLAST LTD","BK7508":"医药生物股","BK7501":"新冠治疗股"},"translate_title":"Euroz Hartleys表示，Mesoblast结果增强了Cynata Therapeutics候选药物的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"MESO":1.5,"MSB.AU":1,"CYP.AU":1},"content_text":"Cynata Therapeutics' (ASX:CYP) acute graft-versus-host disease (aGvHD) drug candidate, CYP-001's potential has been reinforced by Mesoblast's (ASX:MSB) fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric (aGvHD), generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618617137","isCrawlerRequest":true}